Want to see IN:SENORES full AI Analyst Report?
Senores Pharmaceuticals Ltd. (SENORES) AI Stock Analysis
Senores Pharmaceuticals Ltd.
(NSE:SENORES)
Financial performance drives the score via strong revenue growth and margin gains, supported by positive technical momentum; high valuation from stretched P/E tempers the outlook.
Senores Pharmaceuticals Ltd. (SENORES) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 51.62B
- Dividend Yield
- ―
- Average Volume (3M)
- 24.18K
- Price to Earnings (P/E)
- 36.4
- Beta (1Y)
- 0.88
- Revenue Growth
- 39.71%
- EPS Growth
- 53.21%
- Country
- India
- Employees
- 368
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
Senores Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches marke...
Senores Pharmaceuticals Ltd. Financial Statement Overview
Summary
Exceptional revenue growth over 150% with net margin expansion to 18%, solid balance sheet growth and leverage at 0.37, offset by deeply negative free cash flow from heavy capex.
Income Statement
85Very PositiveBalance Sheet
70PositiveCash Flow
40Negative| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 2.52B | 3.83B | 6.33B |
| Gross Profit | 1.29B | 14.11M | 3.81B |
| EBITDA | 849.50M | 1.08B | 2.15B |
| Net Income | 502.10M | 6.85M | 1.15B |
Balance Sheet | |||
| Total Assets | 12.88B | 145.66M | 16.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.60B | 3.85B | 3.32B |
| Total Debt | 2.41B | 3.15B | 3.42B |
| Total Liabilities | 4.54B | 50.70M | 6.39B |
| Stockholders Equity | 8.14B | 7.86B | 9.34B |
Cash Flow | |||
| Free Cash Flow | -2.27B | -2.03B | -2.03B |
| Operating Cash Flow | -280.86M | -459.20M | 620.50M |
| Investing Cash Flow | -3.34B | -4.29B | -1.21B |
| Financing Cash Flow | 4.39B | 5.73B | -13.30M |
Senores Pharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SENORES, the sentiment is Negative. The current price of 1119.60 is below the 20-day moving average (MA) of 1274.13, below the 50-day MA of 1370.59, and above the 200-day MA of 1115.61, indicating a neutral trend. The MACD of -51.97 indicates Positive momentum. The RSI at 32.36 is Neutral, neither overbought nor oversold. The STOCH value of 26.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SENORES.
Senores Pharmaceuticals Ltd. Peers Comparison
Overall Rating
IN:ABBOTINDIA81Outperform
IN:MARKSANS78Outperform- IN:SENORES63Neutral
IN:SMSPHARMA62Neutral
IN:KOPRAN60.3Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:ABBOTINDIA | 81Outperform | INR 543.84B | 33.98 | ― | 2.05% | 6.29% | 11.18% |
| IN:MARKSANS | 78Outperform | INR 138.96B | 27.37 | ― | 0.29% | 19.59% | 47.58% |
| IN:SENORES | 63Neutral | INR 52.21B | 36.44 | ― | ― | 39.71% | 53.21% |
| IN:SMSPHARMA | 62Neutral | INR 47.93B | 44.66 | ― | 0.08% | 10.25% | 33.78% |
| IN:KOPRAN | 60Neutral | INR 11.56B | 46.85 | ― | 1.24% | 11.96% | -28.48% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SENORES | Senores Pharmaceuticals Ltd. | 1119.70 | 352.90 | 46.02% | |
| IN:ABBOTINDIA | Abbott India Limited | 25783.50 | -2912.45 | -10.15% | |
| IN:KOPRAN | Kopran Limited | 242.10 | 80.25 | 49.58% | |
| IN:MARKSANS | Marksans Pharma Limited | 312.40 | 126.16 | 67.74% | |
| IN:SANOFICONR | Sanofi Consumer Healthcare India Limited | 3515.00 | -1285.51 | -26.78% | |
| IN:SMSPHARMA | SMS Pharmaceuticals Limited | 504.25 | 223.09 | 79.35% |
Senores Pharmaceuticals Ltd. Corporate Events
Senores Pharmaceuticals Moves to Extend Top Leadership Terms
Senores Pharmaceuticals’ Board has approved the re-appointment of Managing Director Swapnil Jatinbhai Shah for a three-year term starting October 15, 2026, subject to shareholder approval via postal ballot. The decision, made on the recommendat...
Senores Pharmaceuticals Reappoints Key Directors, Emphasizing Leadership Continuity
Senores Pharmaceuticals Ltd. has reaffirmed its leadership structure by approving the re-appointment of Managing Director Swapnil Jatinbhai Shah for a further three-year term starting October 15, 2026, subject to shareholder approval via a postal bal...
Senores Pharmaceuticals Reappoints Key Directors to Strengthen Leadership Continuity
As part of its latest corporate governance actions, Senores Pharmaceuticals has approved the re-appointment of Managing Director Swapnil Jatinbhai Shah for a three-year term starting October 15, 2026, subject to shareholder approval via a postal ball...
Senores Pharmaceuticals Releases Q1 FY27 Earnings Call Transcript
Senores Pharmaceuticals Ltd. notified stock exchanges that it has released the official transcript of its Q1 FY27 earnings conference call, held on July 27, 2026. The document has been submitted under regulatory disclosure norms and is also available...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 13, 2026